SPRO (Spero Therapeutics) Operating Cash Flow per Share : $-0.26 (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Spero Therapeutics Operating Cash Flow per Share?

Spero Therapeutics's operating cash flow per share for the three months ended in Jun. 2024 was $-0.35. Spero Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.26.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Spero Therapeutics was -189.90% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 45.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Spero Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

SPRO' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -19.4 Med: 25.55 Max: 57.9
Current: 45.4

During the past 9 years, Spero Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 57.90% per year. The lowest was -19.40% per year. And the median was 25.55% per year.

SPRO's 3-Year OCF Growth Rate is ranked better than
89.22% of 1197 companies
in the Biotechnology industry
Industry Median: 3.5 vs SPRO: 45.40

Spero Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Spero Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Operating Cash Flow per Share Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.75

-3.84

-2.08

-0.21

-0.62

Spero Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.35	0.30	-0.32	0.11	-0.35

Competitive Comparison of Spero Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Spero Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Price-to-Operating-Cash-Flow falls into.

Spero Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Spero Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-32.995	/	52.989
	=	-0.62

Spero Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Jun. 2024 )	=	Cash Flow from Operations (Q: Jun. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2024 )
	=	-18.744	/	53.958
	=	-0.35

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26

Spero Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (NAS:SPRO) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

2HA:Germany

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Executives

Timothy Keutzer	officer: Chief Development Officer	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Ankit Mahadevia	director, officer: See Remarks	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139
Sath Shukla	officer: Chief Financial Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Kamal Hamed	officer: Chief Medical Officer	675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Tamara L Joseph	officer: Chief Legal Officer	32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Aquilo Capital Management, Llc	10 percent owner	ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Kathleen Tregoning	director	C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Cristina Larkin	officer: Chief Operating Officer	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aquilo Capital, L.p.	10 percent owner	ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129
Scott Thomas Jackson	director	303B COLLEGE ROAD EAST, PRINCETON NJ 08540
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Pottage John C Jr	director	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Joel Sendek	officer: Chief Financial Officer	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139